| Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: miniperspective E Vitaku, DT Smith, JT Njardarson Journal of medicinal chemistry 57 (24), 10257-10274, 2014 | 5619 | 2014 |
| Data-mining for sulfur and fluorine: An evaluation of pharmaceuticals to reveal opportunities for drug design and discovery: Miniperspective EA Ilardi, E Vitaku, JT Njardarson Journal of medicinal chemistry 57 (7), 2832-2842, 2014 | 1415 | 2014 |
| A graphical journey of innovative organic architectures that have improved our lives NA McGrath, M Brichacek, JT Njardarson Journal of chemical education 87 (12), 1348-1349, 2010 | 1112 | 2010 |
| Analysis of US FDA-approved drugs containing sulfur atoms KA Scott, JT Njardarson Sulfur Chemistry, 1-34, 2019 | 975 | 2019 |
| Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes MR McDevitt, D Chattopadhyay, BJ Kappel, JS Jaggi, SR Schiffman, ... Journal of Nuclear Medicine 48 (7), 1180-1189, 2007 | 573 | 2007 |
| Beyond C, H, O, and N! Analysis of the elemental composition of US FDA approved drug architectures: Miniperspective BR Smith, CM Eastman, JT Njardarson Journal of Medicinal Chemistry 57 (23), 9764-9773, 2014 | 338 | 2014 |
| From oxiranes to oligomers: Architectures of US FDA approved pharmaceuticals containing oxygen heterocycles MD Delost, DT Smith, BJ Anderson, JT Njardarson Journal of Medicinal Chemistry 61 (24), 10996-11020, 2018 | 333 | 2018 |
| Recent advances in the metal-catalyzed ring expansions of three-and four-membered rings DJ Mack, JT Njardarson Acs Catalysis 3 (2), 272-286, 2013 | 279 | 2013 |
| A survey of the structures of US FDA approved combination drugs P Das, MD Delost, MH Qureshi, DT Smith, JT Njardarson Journal of medicinal chemistry 62 (9), 4265-4311, 2018 | 251 | 2018 |
| The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis C Gaul, JT Njardarson, D Shan, DC Dorn, KD Wu, WP Tong, XY Huang, ... Journal of the American Chemical Society 126 (36), 11326-11337, 2004 | 225 | 2004 |
| Discovery of potent cell migration inhibitors through total synthesis: Lessons from structure− activity studies of (+)-migrastatin JT Njardarson, C Gaul, D Shan, XY Huang, SJ Danishefsky Journal of the American Chemical Society 126 (4), 1038-1040, 2004 | 221 | 2004 |
| PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice MR McDevitt, D Chattopadhyay, JS Jaggi, RD Finn, PB Zanzonico, C Villa, ... Plos one 2 (9), e907, 2007 | 211 | 2007 |
| Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice D Shan, L Chen, JT Njardarson, C Gaul, X Ma, SJ Danishefsky, XY Huang Proceedings of the National Academy of Sciences 102 (10), 3772-3776, 2005 | 187 | 2005 |
| Polymerizations with elemental sulfur: from petroleum refining to polymeric materials T Lee, PT Dirlam, JT Njardarson, RS Glass, J Pyun Journal of the American Chemical Society 144 (1), 5-22, 2021 | 157 | 2021 |
| Highly concise routes to epothilones: The total synthesis and evaluation of epothilone 490 K Biswas, H Lin, JT Njardarson, MD Chappell, TC Chou, Y Guan, ... Journal of the American Chemical Society 124 (33), 9825-9832, 2002 | 143 | 2002 |
| The total synthesis of (+)-migrastatin C Gaul, JT Njardarson, SJ Danishefsky Journal of the American Chemical Society 125 (20), 6042-6043, 2003 | 142 | 2003 |
| Phenols in pharmaceuticals: analysis of a recurring motif KA Scott, PB Cox, JT Njardarson Journal of Medicinal Chemistry 65 (10), 7044-7072, 2022 | 119 | 2022 |
| An update on the nitrogen heterocycle compositions and properties of US FDA-approved pharmaceuticals (2013–2023) CM Marshall, JG Federice, CN Bell, PB Cox, JT Njardarson Journal of Medicinal Chemistry 67 (14), 11622-11655, 2024 | 112 | 2024 |
| Synthetic efforts toward [3.3. 1] bridged bicyclic phloroglucinol natural products JT Njardarson Tetrahedron 67 (40), 7631-7666, 2011 | 97 | 2011 |
| Lewis acid catalyzed [1, 3]-sigmatropic rearrangement of vinyl aziridines M Brichacek, DE Lee, JT Njardarson Organic letters 10 (21), 5023-5026, 2008 | 97 | 2008 |
Edon VitakuDuPont Electronics & IndustrialVerified email at dupont.com